Cargando…

Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors

Pharmacotherapy of acute myeloid leukemia (AML) remains challenging, and the disease has one of the lowest curability rates among hematological malignancies. The therapy outcomes are often compromised by the existence of a resistant AML phenotype associated with overexpression of ABCB1 and ABCG2 tra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sorf, Ales, Sucha, Simona, Morell, Anselm, Novotna, Eva, Staud, Frantisek, Zavrelova, Alzbeta, Visek, Benjamin, Wsol, Vladimir, Ceckova, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352292/ https://www.ncbi.nlm.nih.gov/pubmed/32560251 http://dx.doi.org/10.3390/cancers12061596

Ejemplares similares

PB1790: ABCB1 AS A POTENTIAL BENEFICIAL TARGET OF MIDOSTAURIN IN ACUTE MYELOID LEUKEMIA
por: Sucha, S., et al.
Publicado: (2022)

Purvalanol A, Olomoucine II and Roscovitine Inhibit ABCB1 Transporter and Synergistically Potentiate Cytotoxic Effects of Daunorubicin In Vitro
por: Cihalova, Daniela, et al.
Publicado: (2013)

Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
por: Morell, Anselm, et al.
Publicado: (2020)

Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)
por: Ceckova, Martina, et al.
Publicado: (2018)

Olomoucine II, but Not Purvalanol A, Is Transported by Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1)
por: Hofman, Jakub, et al.
Publicado: (2013)

Better Outcome of Off-Label High-Dose Ceftazidime in Hemato-Oncological Patients with Infections Caused by Extensively Drug-Resistant Pseudomonas Aeruginosa
por: Zavrelova, Alzbeta, et al.
Publicado: (2023)

Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme
por: Vagiannis, Dimitrios, et al.
Publicado: (2020)

CDK9 inhibitors in acute myeloid leukemia
por: Boffo, Silvia, et al.
Publicado: (2018)

Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux
por: Čermáková, Lucie, et al.
Publicado: (2022)

Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3
por: Tavares, Tássia S., et al.
Publicado: (2020)

CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia
por: Liu, Wei, et al.
Publicado: (2021)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
por: De Gregori, Simona, et al.
Publicado: (2023)

Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome
por: Belohlavkova, P, et al.
Publicado: (2021)

An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia
por: Lopez, Sophie, et al.
Publicado: (2016)

The long non-coding RNA CDK6-AS1 overexpression impacts on acute myeloid leukemia differentiation and mitochondrial dynamics
por: Porcù, Elena, et al.
Publicado: (2021)

CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia
por: He, Lixiazi, et al.
Publicado: (2022)

An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia
por: Anshabo, Abel Tesfaye, et al.
Publicado: (2022)

Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
por: Gaur, Tarang, et al.
Publicado: (2023)

Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5)
por: Lizrova Preiningerova, Jana, et al.
Publicado: (2015)

Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis
por: Novotna, Martina, et al.
Publicado: (2020)

Extracorporeal membrane oxygenation to support repeated whole-lung lavage in a patient with pulmonary alveolar proteinosis in life threatening dyspnoe – a case report
por: Krecmerova, Martina, et al.
Publicado: (2015)

Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo
por: Vagiannis, Dimitrios, et al.
Publicado: (2021)

Differential Effects of Omeprazole and Lansoprazole Enantiomers on Aryl Hydrocarbon Receptor in Human Hepatocytes and Cell Lines
por: Novotna, Aneta, et al.
Publicado: (2014)

Application of a Pharmacokinetic Model of Metformin Clearance in a Population with Acute Myeloid Leukemia
por: Ceacareanu, Alice C., et al.
Publicado: (2018)

Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia
por: Jiang, Bo, et al.
Publicado: (2023)

Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?
por: Jiraskova, Lucie, et al.
Publicado: (2019)

Bortezomib suppresses self‐renewal and leukemogenesis of leukemia stem cell by NF‐ĸB‐dependent inhibition of CDK6 in MLL‐rearranged myeloid leukemia
por: Zhou, Bin, et al.
Publicado: (2021)

Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia
por: Gurnari, Carmelo, et al.
Publicado: (2020)

Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia
por: Kang, Dongwoo, et al.
Publicado: (2020)

Mycobacterioses Induced by Mycobacterium abscessus: Case Studies Indicating the Importance of Molecular Analysis for the Identification of Antibiotic Resistance
por: Ryskova, Lenka, et al.
Publicado: (2022)

Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia
por: Leipold, Douglas D., et al.
Publicado: (2018)

Myeloid/T-cell acute lymphoblastic leukemia in children and adults
por: Chiaretti, Sabina, et al.
Publicado: (2011)

Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes:An analysis of four SWOG studies
por: Othus, Megan, et al.
Publicado: (2018)

The Health and Welfare of Rabbits as Indicated by Post-Mortem Findings at the Slaughterhouse
por: Valkova, Lenka, et al.
Publicado: (2021)

Traumatic Injuries Detected during Post-Mortem Slaughterhouse Inspection as Welfare Indicators in Poultry and Rabbits
por: Valkova, Lenka, et al.
Publicado: (2021)

Efficacy of a combination therapy targeting CDK4/6 and autophagy in a mouse xenograft model of t(8;21) acute myeloid leukemia
por: Matsuo, Hidemasa, et al.
Publicado: (2021)

Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis
por: Li, Linzhang, et al.
Publicado: (2022)

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma
por: Leahey, Ann-Marie, et al.
Publicado: (2021)

Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives
por: Russo, Domenico, et al.
Publicado: (2020)

Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia
por: Porazzi, Patrizia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aukm3rl6mpvkct4qh66c5ctd6o